U.S. FDA Reviews Heart Health Risks from mRNA Vaccine

In COVID-19, Latest News by Precision Vaccinations

Massachusetts based Moderna, Inc. provided an update on October 31, 2021, that the U.S. Food and Drug Administration (FDA) had notified the Company that it would require additional time to complete its assessment of Moderna’s recent Emergency Use Authorization (EUA) request.
The new EUA request is for the use of the Moderna COVID-19 vaccine (mRNA-1273) at the 100 µg dose level in adolescents 12 to 17 years of age.

Read More